MKC 1106-MT

Drug Profile

MKC 1106-MT

Alternative Names: MKC 1207; MKC1106-MT; pSEM; Synchrovax™ SEM

Latest Information Update: 11 Feb 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator CTL ImmunoTherapies Corporation
  • Developer Colby Pharmaceuticals; MannKind Corporation
  • Class Cancer vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Malignant melanoma

Most Recent Events

  • 10 Feb 2016 No development reported - Phase-II for Malignant melanoma in USA (Intralymphatic)
  • 13 Nov 2012 MKC 1106-MT licensed to Colby Pharmaceutical Company worldwide
  • 20 Oct 2010 Phase-II clinical trials in Malignant melanoma in USA (Intralymphatic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top